This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Astex Pharmaceuticals Announces Results From Dose Escalation Part Of SGI-110 Phase 1/2 MDS And AML Study In An Oral Presentation At ASH

DUBLIN, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced encouraging Phase I clinical results during a presentation at the American Society of Hematology (ASH) of SGI-110, a novel second generation hypomethylation agent.

Data from the completed SGI-110 dose escalation part of a randomized Phase 1/2 first-in-human clinical trial, in patients with relapsed/refractory intermediate or high-risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) demonstrated a differentiated pharmacokinetic (PK) profile resulting in an extended half-life and exposure to decitabine as delivered by subcutaneous SGI-110. Excellent hypomethylation was achieved with higher doses in the daily regimen up to the Biologically Effective Dose (BED). BED was reached before the Maximum Tolerated Dose (MTD). Of the 17 heavily pretreated relapsed/refractory AML patients who were given therapeutic doses of SGI-110 and achieved adequate hypomethylation, 5 major responses were observed. Treatment was well tolerated by most patients with the most common drug-related adverse events being expected myleosuppression, and Grade 1 injection site pain.   The data was presented at an oral session at the ASH 54th Annual Meeting in Atlanta, Georgia today by Hagop M. Kantarjian, MD, Professor and Department Chair, Department of Leukemia, Cancer Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, TX.

The randomized Phase 1/2 dose escalation part enrolled 78 patients of which 44 patients were on the daily regimen and 34 patients were on the weekly regimen. Sixty four patients had relapsed/refractory AML while 14 patients had MDS. The PK profile of subcutaneous SGI-110 demonstrated a longer therapeutic exposure window to decitabine of at least  8 hours, which is more than double the reported exposure  achieved by Dacogen intravenous infusion (DAC IV), and  a longer decitabine half-life (1.5-2.5 hours) which is up to  4-fold longer than that of  DAC IV.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs